New Zealand markets closed

SeaStar Medical Holding Corporation (ICU)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.7170-0.0020 (-0.28%)
At close: 04:00PM EDT
0.7200 +0.00 (+0.42%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.7190
Open0.7290
Bid0.5593 x 200
Ask0.7197 x 200
Day's range0.6850 - 0.8000
52-week range0.1620 - 2.5000
Volume2,246,612
Avg. volume6,055,024
Market cap46.711M
Beta (5Y monthly)-1.15
PE ratio (TTM)N/A
EPS (TTM)-1.3100
Earnings date14 May 2024 - 18 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.00
  • GlobeNewswire

    SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference

    DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18 at 9:30 a.m. Eastern time. The formal presentation will be followed by a hosted question-and-answer session. Investors int

  • GlobeNewswire

    SeaStar Medical to Restate Financials, Sets Business Update Call for April 17

    Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that it will restate its financial statements for the fiscal year ended December 31, 2022 and for the interim periods ended March 31, 2023, June 30, 2023 and Sep

  • GlobeNewswire

    SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

    Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides updates on the acute kidney injury (AKI) programs it is developing with its patented, first-to-market, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically il